Literature DB >> 1395215

Pathophysiology of congestive heart failure.

W W Parmley1.   

Abstract

Congestive heart failure is a syndrome common in the United States, especially in elderly patients. The most common etiology is coronary artery disease. A number of general factors contribute to the heart failure syndrome, including loss of muscle, decreased myocardial contractility, pressure or volume overload, or restricted filling. All of these factors may play a role in a given patient as, for example, with coronary artery disease. Although systolic dysfunction with a reduced ejection fraction is the most common heart failure syndrome, up to 40% of patients may have a relatively preserved ejection fraction with diastolic dysfunction. As the heart begins to fail, a number of compensatory mechanisms are activated. These include increased heart rate, the Frank-Starling mechanism, increased catecholamines, activation of the renin-angiotensin system, and release of atrial natriuretic peptides. Although these mechanisms are initially helpful to the cardiovascular system, they frequently overshoot, initiating a vicious cycle. For example, with a decrease in cardiac output, there is a reflex increase in systemic vascular resistance in order to maintain perfusion pressure. This increase in resistance, however, acts as a load on the left ventricle and further reduces cardiac output. The best evidence for the existence of this vicious cycle is the beneficial change in hemodynamics produced by vasodilator drugs and the ACE inhibitors. Thus, an understanding of pathophysiology allows for the selection of rational therapy. An unresolved problem in heart failure patients is how best to reduce the high incidence of sudden death, which is one of the major challenges for the future.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1395215

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  5 in total

1.  The in vivo role of p38 MAP kinases in cardiac remodeling and restrictive cardiomyopathy.

Authors:  P Liao; D Georgakopoulos; A Kovacs; M Zheng; D Lerner; H Pu; J Saffitz; K Chien; R P Xiao; D A Kass; Y Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-02       Impact factor: 11.205

Review 2.  Reassessment of digoxin and other low-dose positive inotropes in the treatment of chronic heart failure.

Authors:  J Tauke; D Han; M Gheorghiade
Journal:  Cardiovasc Drugs Ther       Date:  1994-10       Impact factor: 3.727

3.  Patient-specific modeling of cardiovascular and respiratory dynamics during hypercapnia.

Authors:  L M Ellwein; S R Pope; A Xie; J J Batzel; C T Kelley; M S Olufsen
Journal:  Math Biosci       Date:  2012-10-06       Impact factor: 2.144

4.  Myocardial force development and structural changes associated with monocrotaline induced cardiac hypertrophy and heart failure.

Authors:  I J M Korstjens; C H F C Rouws; W J van der Laarse; L Van der Zee; G J M Stienen
Journal:  J Muscle Res Cell Motil       Date:  2002       Impact factor: 2.698

5.  Perindopril Improves Cardiac Function by Enhancing the Expression of SIRT3 and PGC-1α in a Rat Model of Isoproterenol-Induced Cardiomyopathy.

Authors:  Zhenyu Zhu; Huihui Li; Wanli Chen; Yameng Cui; Anan Huang; Xin Qi
Journal:  Front Pharmacol       Date:  2020-02-21       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.